Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

Reverse engineering these drugs is a tough challenge without being sued by the three main companies operating in this market (Novo Nordisk, Eli Lilly and Sanofi). Moreover, the latter, in order to ...

Adam Spatacco has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Johnson & Johnson, Moderna, and Novo Nordisk.

Eli Lilly’s big-selling insulin ... as a biosimilar under the name Insulin lispro Sanofi, by the European Commission. In the meantime, Novo Nordisk has responded to the threat from the cut ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. They're both leaders in the areas of insulin and broader diabetes drugs, where they've made significant breakthroughs ...

In the first head-to-head test, Eli Lilly’s Zepbound obesity drug helped people lose significantly more weight than its main competitor, Novo Nordisk’s Wegovy. People taking Zepbound lost 20.2 ...

That's the good news. The bad news is that the bloom may be coming off the GLP-1 rose, which is presumably the reason why not only Eli Lilly but Novo Nordisk and Viking Therapeutics stock are ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY and Novo Nordisk NVO stock. As the major players in the hyper-scale ...